{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:27Z","timestamp":1783075887567,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":530,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.seizure.2014.02.003","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T12:35:55Z","timestamp":1392640555000},"page":"371-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)"],"prefix":"10.1016","volume":"23","author":[{"given":"Daria","family":"Stepanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy G.","family":"Beran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.seizure.2014.02.003_bib0005","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2165\/11208340-000000000-00000","article-title":"Spotlight on levetiracetam in epilepsy","volume":"25","author":"Lyseng-Williamson","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2014.02.003_bib0010","series-title":"Therapeutic Drug Monitoring: Newer Drugs and Biomarkers","author":"DasGupta","year":"2012"},{"issue":"2","key":"10.1016\/j.seizure.2014.02.003_bib0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.seizure.2014.02.003_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"10.1016\/j.seizure.2014.02.003_bib0025","first-page":"1","article-title":"Antiepilepsy drugs: mechanisms of action and pharmacokinetics","volume":"1","author":"Henry","year":"2012","journal-title":"Epilepsy Board Rev Man"},{"key":"10.1016\/j.seizure.2014.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2013.00121","article-title":"Levetiracetam use in the critical care setting","volume":"4","author":"DeWolfe","year":"2013","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2014.02.003_bib0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions \u2013 principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.seizure.2014.02.003_bib0040","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.seizure.2014.02.003_bib0045","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of age and co-medication on levetiracetam pharmacokinetics and tolerability","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2014.02.003_bib0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery in the neonatal period, and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2014.02.003_bib0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1528-1167.2006.00959.x","article-title":"Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures","volume":"48","author":"Baulac","year":"2007","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2014.02.003_bib0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs \u2013 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.003_bib0065","series-title":"Data On File, Smyrna, GA","author":"UCB Pharma, Inc.","year":"2001"},{"key":"10.1016\/j.seizure.2014.02.003_bib0070","first-page":"1289","volume":"21","author":"Weber","year":"2000","journal-title":"Ars Medici"},{"key":"10.1016\/j.seizure.2014.02.003_bib0075","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.seizure.2014.02.003_bib0080","series-title":"Douglass Hanly Moir Macquarie Park Laboratory Method Summary","year":"2013"},{"key":"10.1016\/j.seizure.2014.02.003_bib0085","series-title":"Sonic Healthcare Integra TDM: Free Drug Levels method","year":"2005"},{"key":"10.1016\/j.seizure.2014.02.003_bib0090","series-title":"SSWPS Handbook \u2013 Lamotrigine: Serum\/Plasma","year":"2013"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2014.02.003_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1167.2001.00004.x","article-title":"Pharmacokinetic considerations in prescribing antiepileptic drugs","volume":"42","author":"Faught","year":"2001","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2014.02.003_bib0100","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.seizure.2007.12.007","article-title":"Value of therapeutic drug level monitoring and unbound (free) levels","volume":"17","author":"Chan","year":"2008","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2014.02.003_bib0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eplepsyres.2007.06.002","article-title":"The SKATE\u2122 study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy","volume":"76","author":"Steinhoff","year":"2007","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2014.02.003_bib0110","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","article-title":"Levetiracetam monotherapy \u2013 outcomes from an epilepsy clinic","volume":"20","author":"Stephen","year":"2011","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2014.02.003_bib0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.seizure.2014.02.003_bib0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-3458.2007.00005.x","article-title":"Levetiracetam. Part II. The clinical profile of a novel anticonvulsant drug","volume":"13","author":"De Smedt","year":"2007","journal-title":"CNS Drug Rev"},{"issue":"3","key":"10.1016\/j.seizure.2014.02.003_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1017\/S0317167100011902","article-title":"Meta-analysis of randomized trials on first line and adjunctive levetiracetam","volume":"38","author":"Lo","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.seizure.2014.02.003_bib0130","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.003_bib0135","first-page":"1","article-title":"Levetiracetam monotherapy","volume":"9","author":"Korby","year":"2003","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2014.02.003_bib0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0253-7613.75675","article-title":"Effect of esomeprazole on the pharmacokinetics of carbamazepine","volume":"43","author":"Medhi","year":"2011","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2014.02.003_bib0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00007691-198206000-00004","article-title":"Interaction between valproic acid and carbamazepine: an in vitro study of protein binding","volume":"4","author":"Mattson","year":"1982","journal-title":"Ther Drug Monit"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:44:18Z","timestamp":1761011058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131114000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1059131114000545"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2014.02.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2014.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}